About Us
The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) aims to establish a clear vision of the priority innovations and technologies in vaccine and vaccinology necessary to address infectious and non-infectious threats of importance to public health in Europe and beyond. The roadmap – expected to be finalised by December 2015 – will inform strategic decisions on the priorities for future vaccine investment in innovation and technological development at the level of the EU as well as of individual Member States. The project is key to strengthen Europe ́s competitiveness and leading position in vaccinology, ensuring that Europe will maintain its leadership position and capacity to tackle unmet medical needs. Additional goals include favouring a more structured vaccine innovation agenda, tackling changing medical needs and supporting strained healthcare system budgets.
THE PROJECT
Through a consultation process involving experts from public health and regulatory bodies, small and medium-sized enterprises (SME), large industry, academia, research organisations, civil society organisations, as well as funding and policy bodies, the project will analyse the entire vaccine innovation chain, from needs identification and conceptualisation to discovery and development, including interventions necessary to improve education curricula, and vaccine perception and awareness by the public.
THE CONSORTIUM
The IPROVE consortium comprises four renowned organisations in the vaccine field in Europe: Vaccines Europe (VE), a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA) representing all major research-based vaccine global companies as well SMEs operating in Europe; the European Vaccine Initiative (EVI), a leading European Product Development Partnership supporting the development of effective, accessible, and affordable vaccines against diseases of poverty; the Sclavo Vaccines Association (SVA), a non-profit association whose main objective is to promote vaccine research targeted towards the discovery and study of advanced immunisation technologies; and EATRIS, a European consortium of 69 academic institutions of excellence in translational research, working together to advance candidates into clinical development.
DETAILS OF IPROVE PROJECT
START DATE
01/12/2013
END DATE
31/03/2016
PROJECT COST
€623,419.40
EU CONTRIBUTION
€496,367
COORDINATOR
Vaccines Europe/EFPIA
PROJECT CONSORTIUM
VE/EFPIA (www.vaccineseurope.eu)
Vaccines Europe (VE), a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing all major research-based vaccine global companies as well as SMEs operating in Europe.
EVI (www.euvaccine.eu)
The European Vaccine Initiative (EVI), a leading European Product Development Partnership supporting the development of effective, accessible and affordable vaccines against diseases of poverty.
SVA (www.sclavo.org)
The Sclavo Vaccines Association (SVA), a non-profit association whose main objective is to promote vaccine research targeted towards the discovery and study of advanced immunisation technologies.
EATRIS (www.eatris.eu)
EATRIS, a European consortium of 75 academic institutions of excellence in translational research, working together to advance candidates into clinical development